Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
Company AIP notice of proposed sale of common stock by an insider. The filing lists 6003 shares of Common stock from Restricted Stock Units with an effective date of 07/01/2026. It also discloses recent 10b5-1 sales by Paul Lawrence Alpern of 6,500 shares on 07/01/2026 and 12,502 shares on 06/01/2026, with proceeds shown in the excerpt.
BAYVIEW LEGACY, LLC reported proposed sales of Common Stock of AIP under Rule 144 via 10b5-1 arrangements. The notice lists 181,338 shares on 07/01/2026 with proceeds of $8,243,335.34 and 192,686 shares on 07/02/2026 with proceeds of $6,998,663.82. The broker shown is Morgan Stanley Smith Barney LLC.
Arteris, Inc. VP and General Counsel Paul L. Alpern reported multiple transactions in the company’s common stock on July 1, 2026. He sold a total of 6,500 shares in open-market transactions at weighted average prices ranging from about $43.70 to $47.50, carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 23, 2026. On the same date, he exercised stock options to acquire 6,500 shares of common stock at exercise prices of $9.28 and $0.56 per share. Following these transactions, he continues to hold more than 80,000 shares of Arteris common stock directly.
Arteris, Inc. director and CEO K. Charles Janac reported indirect open-market sales of 181,338 shares of Arteris common stock on July 1, 2026 through Bayview Legacy, LLC, where he serves as manager. The sales were made under a Rule 10b5-1 trading plan adopted on December 12, 2025, at weighted-average prices reported between $44.0606 and $47.0752 per share.
Following these transactions, Bayview Legacy, LLC beneficially owned 8,747,733 shares of Arteris common stock indirectly attributed to Janac. Separate holding entries show an additional 196,729 shares held directly and 56,252 shares held through the Charles and Lydia Janac Trust.
Arteris, Inc. major holder Bayview Legacy, LLC reported selling common stock in multiple open-market transactions. On July 1, 2026, Bayview executed four sales totaling 181,338 shares of Arteris common stock at weighted average prices between $44.0606 and $47.0752.
The trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted by K. Charles Janac, who manages Bayview Legacy, LLC and is deemed to have voting and dispositive power over the shares.
Arteris, Inc. director Saiyed Atiq Raza reported significant insider sales of Arteris (AIP) common stock. On 2026-07-01, a revocable trust for which he serves as trustee sold an aggregate of 70,000 shares in multiple open-market transactions at weighted-average prices including $47.1004, $44.9884, $43.9796 and $46.1987 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After the sales, the trust held 119,041 shares of common stock, and Raza also held 4,703 shares directly.
Bayview Legacy, LLC reported proposed resale of 700,000 shares of Common Stock, acquired 11/05/2013, on Nasdaq. The filing lists recent automated sales executed under a 10b5-1 plan: 70,000 shares sold on each of 04/08/2026, 05/08/2026, and 06/08/2026, with proceeds of $1,332,782, $2,183,986, and $2,443,434, respectively.
Shares outstanding are shown as 46,171,982 as of 07/01/2026. The resale is described as a private acquisition from the issuer or an affiliate, and transactions were effected pursuant to a 10b5-1 plan per the sales entries.
Insider notice to sell shares under Form 144. The filing lists 70,000 shares of Common stock identified as previously exercised stock options to be sold. The excerpt also shows multiple 10b5-1 sales during the past three months, including transactions of 90,000, 72,940, and 70,000 shares on various dates. The filing references NASDAQ and contains a 07/01/2026 date.
Arteris, Inc. Chief Operating Officer Laurent R. Moll reported an open-market sale of 39,541 shares of Common Stock at a price of $43.15 per share on June 16, 2026. This represents a partial reduction of his direct holdings rather than a full exit.
After the transaction, Moll directly holds 227,296 shares of Arteris common stock. A footnote explains that this total includes 1,307 shares acquired on May 21, 2026 through the company’s Employee Stock Purchase Plan, reflecting ongoing participation in an employee equity program even alongside the reported sale.
AIP filed a Form 144 notice reporting proposed dispositions of Common Stock by an identified selling person.
The filing lists restricted stock vesting entries under a registered plan dated 09/09/2024 (25,850 shares) and 09/03/2024 (13,691 shares), and shows multiple actual sales by Laurent Moll in April 2026, including 13,448, 1,003, 990, 1,552, and 5,602 shares on specific dates with corresponding proceeds.